An act to amend Section 123505 of the Health and Safety Code, relating to public health. An act to amend Section 127502 of the Health and Safety Code, relating to health care.
AB 1474 makes two changes to the Health and Safety Code. Its main substantive change is to California’s health care cost-target framework administered by the Office of Health Care Affordability. The bill would require the board and office to adjust statewide and sector-specific cost targets when prescription drug costs are projected to grow faster than the applicable target, and it directs the methodology used to set those targets to account for increased prescription-drug expenditures. The bill also retains and restates existing provisions governing cost targets for providers, fully integrated delivery systems, payers, and individual health care entities, including public reporting, risk adjustment, equity adjustments, and exemptions for certain providers.
The second part of the bill makes a technical, nonsubstantive change to the statutory goals for California’s community-based comprehensive perinatal health care system. Those goals remain focused on reducing perinatal, maternal, and infant mortality and morbidity and supporting comprehensive prenatal care that helps prevent prematurity and low birth weight. The perinatal section does not appear to change policy direction or program scope.
The bill’s impact on state law is to add prescription drug cost growth as a specific factor that can justify upward adjustment of health care cost targets for providers and fully integrated delivery systems. In practice, that would affect how the Office of Health Care Affordability develops and enforces annual cost targets under the California Health Care Quality and Affordability Act, potentially giving health care entities more room in their targets when drug spending rises faster than the benchmark. The bill does not create an appropriation or local program and appears to operate within existing state oversight structures.
The general sentiment reflected in the available record is neutral to supportive, but limited. There are no committee transcript snippets or recorded votes showing opposition or debate, and the bill was still in the Assembly Health Committee process when it was filed with the Chief Clerk under Joint Rule 56. The absence of recorded controversy suggests the measure was treated as a technical or targeted policy adjustment rather than a broad or highly contentious overhaul.
No specific points of contention are documented in the provided materials. Based on the text, any policy debate would likely center on whether prescription drug spending should trigger higher cost targets, how the Office should verify projected drug-cost growth, and whether such adjustments could weaken cost-containment goals. Other possible issues include how the new adjustment interacts with labor-cost adjustments, Medi-Cal-related methodology provisions, and the treatment of exempted providers.
AB 1474 would amend Health and Safety Code Section 127502 to require the Office of Health Care Affordability’s cost-target methodology to account for prescription drug cost growth and to adjust provider or fully integrated delivery system targets when drug costs are projected to outpace the applicable target. This would affect statewide health care cost targets, sector-specific targets, and the enforcement framework for annual targets beginning with the 2025 reporting year and 2026 enforcement year structure already in law. The bill also makes a technical, nonsubstantive update to Health and Safety Code Section 123505 regarding community-based perinatal care goals, leaving the substance of that program unchanged.
The available record suggests a largely neutral and procedural posture, with no recorded committee testimony or vote breakdown indicating organized support or opposition. The bill had not advanced beyond committee filing at the time provided, and the absence of recorded debate implies it was viewed as a targeted adjustment to existing health care cost-target law rather than a controversial policy shift.
No explicit contention is documented in the provided materials. If debated, the likely fault lines would be whether prescription drug inflation should justify higher cost targets, how much discretion the Office of Health Care Affordability should have in validating projected drug-cost increases, and whether the adjustment could dilute the bill’s broader cost-containment objectives. Stakeholders most likely to care would include hospitals, integrated delivery systems, insurers, Medi-Cal stakeholders, and prescription drug pricing advocates or critics.